The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas
Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus’ scientific and clinical efforts to develop targeted radiotherapeutics for central nervous system (CNS) cancers
NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.
